Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025Future OncologyOpen Access

Zanubrutinib in the treatment of Waldenström Macroglobulinemia

View Full Paper
Ask AI
Bookmark
Share

Authors

EGE. W. GoodallSOStephen Opat

Discussion

Loading...

Member takes

Overview

Clinical review reveals zanubrutinib's effectiveness in WM, highlighting MYD88 mutations and BTK inhibition implications.

Key Points

  • Zanubrutinib significantly improves treatment outcomes in WM patients with MYD88 mutations, indicating its effectiveness.
  • Clinical results show that zanubrutinib has better tolerability and lower discontinuation rates compared to ibrutinib in WM therapy.
  • BTK inhibitors like zanubrutinib offer promise for WM management, but patients with CXCR4 and TP53 mutations still show poor outcomes.
  • The review suggests further exploration of zanubrutinib's role within diverse genetic subtypes to enhance treatment strategies.

Cite This Study

Goodall et al. (2025) studied this question.

synapsesocial.com/papers/68d44b2231b076d99fa541d0https://doi.org/10.1080/14796694.2025.2558351
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia2018 · 181 citations
  2. 2Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase2006 · 682 citations
  3. 3Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions2014 · 309 citations
  4. 4Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis2018 · 25 citations
  5. 5CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies2020 · 63 citations